{"filings":[{"id":92509,"accession_number":"0001104659-26-055629","cik":1377121,"company_name":"Protagonist Therapeutics, Inc","ticker":"PTGX","form_type":"8-K","filed_at":"2026-05-05T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Protagonist Q1 net income $3.8M on ICOTYDE approval milestone; cash $620M, rusfertide opt-out fee $200M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net income $3.8M ($0.05 diluted EPS) vs net loss $11.7M in Q1 2025; revenue $56.4M incl. $50M ICOTYDE milestone from J&J.","Cash, equivalents & marketable securities $620.3M as of March 31, 2026; expected runway through at least 2028.","ICOTYDE FDA-approved March 18 for plaque psoriasis; Protagonist eligible for up to $580M in milestones and 6-10% tiered royalties.","Exercised rusfertide opt-out April 28, triggering $200M payment due; eligible for additional $200M opt-out fee and $75M milestone plus up to $775M sales milestones and 14-29% royalties.","Rusfertide NDA granted Priority Review; PDUFA date August 2026. PN-881 Phase 1 completion by mid-2026, Phase 2 initiation expected year-end."],"consensus_eps_estimate":null,"consensus_eps_actual":0.05,"consensus_revenue_estimate":null,"consensus_revenue_actual":56368000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":6488374147.234517,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":103390,"accession_number":"0001104659-26-019658","cik":1377121,"company_name":"Protagonist Therapeutics, Inc","ticker":"PTGX","form_type":"8-K","filed_at":"2026-02-25T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Protagonist Q4 net loss $44.4M ($0.69/share); rusfertide opt-out expected Q2 2026","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2025 net loss $44.4M ($0.69 per share) vs Q4 2024 net income $131.7M ($2.11 per share); FY2025 loss $130.1M ($2.05) vs FY2024 income $275.2M ($4.47).","License revenue fell to $7.4M in Q4 2025 from $170.6M in Q4 2024; FY2025 revenue $46.0M from $434.4M, due to lower milestones.","Cash, equivalents and marketable securities $646M as of Dec 31, 2025; provides runway through at least end of 2028.","Rusfertide NDA filed; company expects to opt out of the 50:50 profit/loss sharing with Takeda in a 90-day window opening in Q2 2026.","ICOTYDE regulatory decision anticipated in 2026 with potential launch this year; PN-881 Phase 1 completion by mid-2026; new preclinical candidates added."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.05,"consensus_revenue_estimate":null,"consensus_revenue_actual":46016000.0,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":6488374147.234517,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":103389,"accession_number":"0001104659-26-002724","cik":1377121,"company_name":"Protagonist Therapeutics, Inc","ticker":"PTGX","form_type":"8-K","filed_at":"2026-01-12T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Protagonist updates pipeline; icotrokinra NDA Jul '25, rusfertide NDA Dec '25; Phase 3 UC/CD initiated","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Icotrokinra (oral IL-23R) NDA for psoriasis filed Jul '25; Phase 3 ICONIC-UC and ICONIC-CD initiated Q4 '25; superiority vs deucravacitinib achieved.","Rusfertide (hepcidin mimetic) NDA for polycythemia vera submitted Dec 29 '25; Phase 3 VERIFY met primary endpoint, p<0.0001.","PN-881 (oral IL-17) Phase 1 started Q4 '25; PN-477sc triple agonist Ph1 initiation mid-'26; PN-8047 oral hepcidin dev candidate nominated Q4 '25.","Up to $630M milestones from J&J plus 6-10% royalties; $200M opt-out payment from Takeda for rusfertide plus additional milestones.","Total potential sales milestones from icotrokinra and rusfertide up to $1.2B."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":6488374147.234517,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":119627,"accession_number":"0001104659-25-107753","cik":1377121,"company_name":"Protagonist Therapeutics, Inc","ticker":"PTGX","form_type":"8-K","filed_at":"2025-11-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Protagonist Q3 net loss $39.3M (-$0.62); cash $678.8M; icotrokinra filed, rusfertide NDA expected Q4","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $39.3M ($0.62 diluted EPS loss) vs $33.2M loss in Q3 2024.","Cash $678.8M, up from $559.2M at year-end 2024; provides runway through at least end 2028.","Icotrokinra NDA submitted to FDA (July) and EMA (September) for moderate-to-severe plaque psoriasis.","Rusfertide granted FDA Breakthrough Therapy designation; Phase 3 VERIFY 52-week data at ASH Dec 2025; NDA filing expected Q4 2025.","First patient dosed in Phase 1 for oral IL-17 antagonist PN-881."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.35,"consensus_revenue_estimate":null,"consensus_revenue_actual":38579000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":6488374147.234517,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":136202,"accession_number":"0001104659-25-074719","cik":1377121,"company_name":"Protagonist Therapeutics, Inc","ticker":"PTGX","form_type":"8-K","filed_at":"2025-08-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Protagonist Q2 net loss $34.8M; icotrokinra NDA filed, rusfertide NDA on track","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $34.8M ($0.55/share) vs $30.6M in Q2 2024; license revenue $5.5M from Takeda.","Cash $673M as of June 30, sufficient for runway through at least end 2028.","NDA for icotrokinra (moderate-to-severe plaque psoriasis) submitted to FDA in July.","Rusfertide NDA for polycythemia vera expected Q4 2025; Phase 3 VERIFY data presented at ASCO.","Pipeline: PN-477 oral/subcutaneous triple agonist for obesity selected; PN-881 IL-17 antagonist."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.73,"consensus_revenue_estimate":null,"consensus_revenue_actual":33867000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":6488374147.234517,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":153281,"accession_number":"0001104659-25-063038","cik":1377121,"company_name":"Protagonist Therapeutics, Inc","ticker":"PTGX","form_type":"8-K","filed_at":"2025-06-26T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Protagonist Therapeutics shareholders elect directors, approve say-on-pay, ratify auditor","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Harold Selick and Bryan Giraudo elected Class III directors with ~83% and ~79% of votes cast, respectively.","Non-binding advisory vote on executive compensation approved: 50.8M for, 2.9M against, 0.3M abstentions.","Ratification of Ernst & Young as independent auditor for FY 2025 approved: 55.5M for, 74k against, 0.4M abstentions.","No other proposals were submitted; broker non-votes were 1,918,517 for all director and say-on-pay items."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.15,"market_cap_usd":6488374147.234517,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":153280,"accession_number":"0001104659-25-045073","cik":1377121,"company_name":"Protagonist Therapeutics, Inc","ticker":"PTGX","form_type":"8-K","filed_at":"2025-05-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Protagonist Q1 EPS -$0.19; rusfertide Phase 3 positive, ASCO plenary June 1","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash $697.9M (up from $559.2M Dec 2024); net loss $11.7M (-$0.19/sh) vs income $207.3M in Q1 2024.","Rusfertide Phase 3 VERIFY in PV met primary endpoint (p<0.0001) and all 4 key secondaries; ASCO plenary June 1, conf call June 2.","Icotrokinra Phase 3 ICONIC-LEAD data presented at AAD and WCPD; Phase 2b ANTHEM-UC positive, full data later in 2025.","Revenue $28.3M includes $22.8M rusfertide milestone recognition; vs $255M Q1 2024 with Takeda upfront.","Pipeline: oral IL-17 antagonist PN-881 to enter clinic in 2025; cash runway through at least end of 2028."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.19,"consensus_revenue_estimate":null,"consensus_revenue_actual":28321000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":6488374147.234517,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":172057,"accession_number":"0001104659-25-026135","cik":1377121,"company_name":"Protagonist Therapeutics, Inc","ticker":"PTGX","form_type":"8-K","filed_at":"2025-03-20T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Protagonist transitions rusfertide NDA regulatory leadership to Takeda","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Takeda to lead regulatory strategy and NDA preparation for rusfertide in polycythemia vera; transition underway.","Protagonist remains primarily responsible for clinical development activities through NDA filing.","Decision made under License and Collaboration Agreement dated January 31, 2024, as amended."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":6488374147.234517,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":172052,"accession_number":"0001104659-25-022615","cik":1377121,"company_name":"Protagonist Therapeutics, Inc","ticker":"PTGX","form_type":"8-K/A","filed_at":"2025-03-11T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Icotrokinra shows positive Phase 2b UC (corrected p-value) and Phase 3 PsO top-line data","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Phase 2b ANTHEM-UC: highest dose achieved 63.5% clinical response and 30.2% clinical remission at Wk12 vs 27.0% and 11.1% placebo; p-values corrected to <0.001 and <0.01.","Phase 3 ICONIC-LEAD: 65% IGA 0/1 and 50% PASI 90 at Wk16; at Wk24: 74% IGA 0/1, 65% PASI 90; 46% completely clear skin.","Phase 3 ICONIC-ADVANCE 1&2: met co-primary endpoints vs placebo; superior to deucravacitinib on all key secondary endpoints at Wk16 and Wk24.","Initiation of ICONIC-ASCEND: first head-to-head study of oral icotrokinra vs injectable biologic (ustekinumab) in moderate-to-severe PsO."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":6488374147.234517,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":172056,"accession_number":"0001104659-25-021986","cik":1377121,"company_name":"Protagonist Therapeutics, Inc","ticker":"PTGX","form_type":"8-K","filed_at":"2025-03-10T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Icotrokinra Phase 3 PsO hits 46% complete skin clearance; UC Phase 2b meets endpoint","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Phase 3 ICONIC-LEAD: 46% of icotrokinra patients achieved IGA 0 (completely clear skin) at Week 24; 74% IGA 0/1.","ICONIC-ADVANCE 1&2 met co-primary endpoints and showed superiority over deucravacitinib at Weeks 16 and 24; head-to-head vs ustekinumab (ICONIC-ASCEND) initiated.","Phase 2b ANTHEM-UC: 63.5% clinical response at highest dose at Week 12 vs 27.0% placebo (p<0.001); 30.2% clinical remission vs 11.1% (p<0.001).","Both studies show favorable safety; AEs similar to placebo. Icotrokinra is a first-in-class oral IL-23 receptor antagonist.","Results support potential paradigm shift in plaque psoriasis and ulcerative colitis; partner J&J advancing program."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":1.0,"calibrated_materiality_score":1.0,"market_cap_usd":6488374147.234517,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":172055,"accession_number":"0001104659-25-019516","cik":1377121,"company_name":"Protagonist Therapeutics, Inc","ticker":"PTGX","form_type":"8-K","filed_at":"2025-03-03T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Protagonist and Takeda announce positive Phase 3 topline data for rusfertide in polycythemia vera; primary endpoint met","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["77% of rusfertide patients achieved clinical response vs 33% placebo (p<0.0001) during weeks 20-32.","Mean phlebotomies per patient: 0.5 rusfertide vs 1.8 placebo (p<0.0001) over 32 weeks (EU primary endpoint).","All four key secondary endpoints met, including hematocrit control and patient-reported outcomes.","Safety profile consistent with prior studies; no new safety signals; serious AEs not drug-related.","NDA filing for rusfertide expected in second half of 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":6488374147.234517,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":172054,"accession_number":"0001104659-25-015897","cik":1377121,"company_name":"Protagonist Therapeutics, Inc","ticker":"PTGX","form_type":"8-K","filed_at":"2025-02-21T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Protagonist reports Q4 net income $131.7M; cash $559.2M; upcoming Phase 3 readouts in March 2025","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net income of $131.7M in Q4 2024 ($2.11 basic EPS) vs $27.3M in Q4 2023; FY 2024 net income $275.2M vs net loss of $79.0M in FY 2023.","License & collaboration revenue of $434.4M for FY 2024, up from $60.0M in FY 2023, including $165M milestone from JNJ.","Cash, equivalents, and marketable securities $559.2M at Dec 31, 2024; plus $165M milestone received Jan 2025; runway through at least end of 2028.","Topline results for rusfertide Phase 3 VERIFY (polycythemia vera) and icotrokinra Phase 2b ANTHEM (ulcerative colitis) expected in March 2025.","Nominated PN-881, an oral IL-17 receptor antagonist; plans to nominate oral obesity candidate in Q2 2025 and oral hepcidin candidate in Q4 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":4.23,"consensus_revenue_estimate":null,"consensus_revenue_actual":434433000.0,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":6488374147.234517,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":172053,"accession_number":"0001104659-25-001304","cik":1377121,"company_name":"Protagonist Therapeutics, Inc","ticker":"PTGX","form_type":"8-K","filed_at":"2025-01-06T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Protagonist Therapeutics appoints Suneel Gupta as EVP, Clinical Development","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Effective Jan 1, 2025, Suneel Gupta transitioned from Chief Development Officer to EVP, Clinical Development.","Gupta, previously CDO, now serves as Executive Vice President, Clinical Development.","No other officer changes were reported in the filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":6488374147.234517,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":189041,"accession_number":"0001104659-24-120165","cik":1377121,"company_name":"Protagonist Therapeutics, Inc","ticker":"PTGX","form_type":"8-K","filed_at":"2024-11-18T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Protagonist announces positive Phase 3 results for icotrokinra; earns $165M milestone","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["ICONIC-LEAD met co-primary endpoints: 64.7% achieved IGA 0/1, 49.6% PASI 90 at week 16 vs placebo 8.3% and 4.4%.","ICONIC-TOTAL met primary endpoint of IGA 0/1 at week 16; results in difficult-to-treat areas.","Earned $165M milestone under amended collaboration with Janssen; payment expected Q1 2025.","Company remains eligible for up to $630M in future milestones and tiered royalties of 6-10% on net sales.","Upcoming catalysts H1 2025: Phase 2b ulcerative colitis data, PsA Phase 3 start, superiority data vs deucravacitinib."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":6488374147.234517,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":189040,"accession_number":"0001104659-24-115303","cik":1377121,"company_name":"Protagonist Therapeutics, Inc","ticker":"PTGX","form_type":"8-K","filed_at":"2024-11-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Protagonist Q3 net loss of $33.2M, cash $583M; key readouts expected in Q4 2024 and Q1 2025","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $33.2M ($0.54 per share) vs $34.1M loss in prior-year Q3.","Cash, equivalents and marketable securities $583.3M as of Sep 30, up from $341.6M at Dec 31, 2023.","License & collaboration revenue $4.7M from Takeda deal; $263.8M for nine months includes $255M upfront.","Top line results expected: JNJ-2113 Phase 3 psoriasis (ICONIC-LEAD/TOTAL) in Q4 2024; Phase 2b UC (ANTHEM) and rusfertide Phase 3 (VERIFY) in Q1 2025.","Anticipates nomination of oral IL-17 development candidate in Q4 2024; hepcidin and obesity candidates in 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":2.22,"consensus_revenue_estimate":null,"consensus_revenue_actual":263795000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":6488374147.234517,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":205521,"accession_number":"0001104659-24-101688","cik":1377121,"company_name":"Protagonist Therapeutics, Inc","ticker":"PTGX","form_type":"8-K","filed_at":"2024-09-20T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Director Daniel N. Swisher Jr. resigns from Protagonist board; board reduced to six","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Daniel N. Swisher Jr. resigned from the Board effective September 17, 2024; no disagreement with company operations.","Swisher will continue as an advisor to the company under an advisory agreement.","Sarah A. O'Dowd appointed to the Audit Committee effective September 19, 2024.","Board size reduced from seven to six members concurrent with Swisher's resignation."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":6488374147.234517,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":205520,"accession_number":"0001104659-24-086088","cik":1377121,"company_name":"Protagonist Therapeutics, Inc","ticker":"PTGX","form_type":"8-K","filed_at":"2024-08-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Protagonist Q2 net loss $30.6M; cash $595.4M; JNJ-2113 Phase 3 data expected Q4 2024","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 net loss of $30.6M ($0.50/share) vs $38.5M loss in Q2 2023; six-month net income $176.7M from Takeda upfront.","Cash, equivalents and marketable securities of $595.4M as of June 30, 2024; runway through end of 2027.","JNJ-2113 Phase 3 ICONIC-LEAD and ICONIC-TOTAL in psoriasis primary endpoint completion expected Q4 2024.","Phase 2b ANTHEM in ulcerative colitis primary endpoint completion also expected Q4 2024; Phase 3 VERIFY rusfertide topline due Q1 2025.","Dr. Newman Yeilding appointed Chief Scientific Advisor effective August 1, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":2.77,"consensus_revenue_estimate":null,"consensus_revenue_actual":259120000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":6488374147.234517,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":222449,"accession_number":"0001104659-24-075162","cik":1377121,"company_name":"Protagonist Therapeutics, Inc","ticker":"PTGX","form_type":"8-K","filed_at":"2024-06-26T23:59:59+00:00","items":["5.03","5.07","9.01"],"status":"ready","headline":"Protagonist Therapeutics shareholders approve doubling of authorized common shares to 180M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Shareholders approved amendment to increase authorized common shares from 90M to 180M, effective June 21, 2024.","Three Class II directors elected: Sarah O'Dowd, William Waddill, and Rusty Williams.","Advisory vote on executive compensation approved: 33.9M for, 9.3M against.","Ratification of Ernst & Young as independent auditor for FY2024 approved: 49.3M for, 115k against.","All four proposals passed; no other matters submitted at annual meeting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":6488374147.234517,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":222448,"accession_number":"0001104659-24-058036","cik":1377121,"company_name":"Protagonist Therapeutics, Inc","ticker":"PTGX","form_type":"8-K","filed_at":"2024-05-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Protagonist Q1 net income $207.3M on $255M Takeda revenue; cash runway through Q4 2027","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net income of $207.3M ($3.26 diluted EPS) vs net loss of $33.7M in Q1 2023; revenue $255M from Takeda rusfertide license.","Cash, equivalents & marketable securities $322.6M at March 31, 2024; extended runway through Q4 2027 including $300M upfront from Takeda.","Phase 3 ICONIC LEAD and ICONIC TOTAL trials of JNJ-2113 in psoriasis completed enrollment; Phase 3 ICONIC ADVANCE studies ongoing.","Expect to nominate oral IL-17 antagonist development candidate by end of 2024.","Rusfertide VERIFY study top-line data expected by Q1 2025; potential deal value with Takeda up to $630M plus profit share/royalties."],"consensus_eps_estimate":null,"consensus_eps_actual":3.26,"consensus_revenue_estimate":null,"consensus_revenue_actual":254953000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":6488374147.234517,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":241975,"accession_number":"0001104659-24-028208","cik":1377121,"company_name":"Protagonist Therapeutics, Inc","ticker":"PTGX","form_type":"8-K","filed_at":"2024-02-27T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Protagonist reports Q4 profit, $300M Takeda deal extends cash runway through 2027","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Entered worldwide Takeda collaboration for rusfertide; $300M upfront, US profit share, opt-out up to $400M.","Q4 net income $27.3M ($0.45 EPS) vs loss $34.2M in Q4 2022; full year loss $79M improved from $127.4M.","Cash $341.6M; runway extended through Q4 2027 including $300M Takeda upfront.","Earned $60M in JNJ-2113 milestones from J&J in Q4; VERIFY Phase 3 enrollment on track for Q1 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":6488374147.234517,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":241974,"accession_number":"0001104659-24-008787","cik":1377121,"company_name":"Protagonist Therapeutics, Inc","ticker":"PTGX","form_type":"8-K","filed_at":"2024-01-31T23:59:59+00:00","items":["1.01"],"status":"ready","headline":"Protagonist Therapeutics signs $300M upfront collaboration with Takeda for rusfertide","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Takeda pays $300M upfront within 30 days of HSR clearance; 50/50 profit-loss share in U.S.","Tiered royalties of 10-17% in ex-US territory; up to 29% if opt-out exercised.","Milestones up to $330M (no opt-out) or up to $975M (with opt-out); plus $400M opt-out payment potential.","Takeda leads global commercialization; Protagonist holds option to co-detail in U.S.","Takeda may terminate for convenience after Phase 3 data or 3rd anniversary of effective date."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":6488374147.234517,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}